BARD1 and neoplasm: RT-PCR showed that while SRPK1 or Tip60 overexpression alone marginally upregulated Bcl-xS and MCL-1S in cisplatin-treated 231R (Fig. 6b, lanes 2 and 4; Supplementary Fig. 12c), their concurrent overexpression dramatically increased the relative abundance of these pro-apoptotic variants, as well as the tumour suppressive BARD1-FL and BARD1α, which was reversed when SRPK1 acetylation was prevented (Fig. 6b, lanes 6 and 7; Supplementary Fig. 12c, lanes 5–7), suggesting that SRPK1 acetylation may favour pro-apoptotic splicing.